Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125 beyond PD-1 Refractory Melanoma

NEXT STORY
Cancer Genetics’ Unique Tissue of Origin Test (TOO®) Receives Special FDA 510(k) Clearance
PREV STORY
G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FMW Media, Inc.’s New to The Street TV Announces its 5 TV Interviews Being Broadcasted On Fox Business Network, Tonight, Monday, August 2, 2021 @ 10:30 PM PT and Tomorrow, Tuesday, August 3, 2021 @ 10:30 PM PT

author_avatar
NASDAQ Market News

NewLink Genetics Awarded $25 Million Contract from BARDA for Investigational Ebola Zaire Vaccine (V920)

AMES, Iowa, Oct. 04, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), announced today ...

author_avatar
NASDAQ Market News

Amicus Therapeutics Announces Planned Analysis of Primary Endpoints in Phase 3 Epidermolysis Bullosa Study

CRANBURY, N.J., May 19, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD),  has completed ...

author_avatar
NASDAQ Market News